Fluoropharma Medical
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. The company was founded in 2003 and is headquartered in Montclair, New Jersey.
Fluoropharma Medical (FPMI) - Net Assets
Latest net assets as of December 2016: $-10.18 Million USD
Based on the latest financial reports, Fluoropharma Medical (FPMI) has net assets worth $-10.18 Million USD as of December 2016.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($334.76K) and total liabilities ($10.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-10.18 Million |
| % of Total Assets | -3040.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -838.69% |
| 10-Year Change | N/A |
| Growth Volatility | 60.09 |
Fluoropharma Medical - Net Assets Trend (2007–2016)
This chart illustrates how Fluoropharma Medical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fluoropharma Medical (2007–2016)
The table below shows the annual net assets of Fluoropharma Medical from 2007 to 2016.
| Year | Net Assets | Change |
|---|---|---|
| 2016-12-31 | $-10.18 Million | -29.50% |
| 2015-12-31 | $-7.86 Million | -63.87% |
| 2014-12-31 | $-4.80 Million | -354.04% |
| 2013-12-31 | $-1.06 Million | -176.66% |
| 2012-12-31 | $1.38 Million | -56.47% |
| 2011-12-31 | $3.17 Million | +5633.11% |
| 2010-12-31 | $-57.22K | -28.92% |
| 2009-12-31 | $-44.38K | -52.64% |
| 2008-12-31 | $-29.08K | -129.69% |
| 2007-12-31 | $-12.66K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fluoropharma Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3510491600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2016)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $34.08K | % |
| Other Components | $24.96 Million | % |
| Total Equity | $-10.18 Million | 100.00% |
Fluoropharma Medical Competitors by Market Cap
The table below lists competitors of Fluoropharma Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ruzy Madencilik ve Enerji Yatirimlari Sanayi ve Ticaret A.S.
IS:RUZYE
|
$3.07K |
|
VELOGIC HOLDING COMPANY LIMITED
SEM:VELG
|
$3.07K |
|
Ba Ria Thermal Power JSC
VN:BTP
|
$3.07K |
|
Sienna Biopharmaceuticals Inc
PINK:SNNAQ
|
$3.08K |
|
Global Blockchain Acquisition Corp. Warrant
NASDAQ:GBBKW
|
$3.06K |
|
MULTISTRADA ARAH SA (QGH.SG)
STU:QGH
|
$3.06K |
|
PRECISE BIOMETRICS (PBCB.SG)
STU:PBCB
|
$3.06K |
|
Grempco
WAR:GRM
|
$3.06K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fluoropharma Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2015 to 2016, total equity changed from -7,860,383 to -10,179,292, a change of -2,318,909.
- Net loss of 2,049,861 reduced equity.
- Other factors decreased equity by 269,048.
Equity Change Factors (2015 to 2016)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.05 Million | -20.14% |
| Other Changes | $-269.05K | -2.64% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Fluoropharma Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.00 | $0.00 | x |
| 2008-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $-0.04 | $0.00 | x |
| 2014-12-31 | $-0.16 | $0.00 | x |
| 2015-12-31 | $-0.26 | $0.00 | x |
| 2016-12-31 | $-0.30 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fluoropharma Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | -65.56% | 4.21x | 0.00x | $-71.46K |
| 2008 | 0.00% | -10.08% | 20.62x | 0.00x | $-13.82K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $98.36K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $474.97K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.38 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.03 Million |
Industry Comparison
This section compares Fluoropharma Medical's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fluoropharma Medical (FPMI) | $-10.18 Million | 0.00% | N/A | $3.07K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |